期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 25, 期 4, 页码 188-196出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2013.12.007
关键词
statin; HMG-CoA reductase; prostate cancer; cholesterol; androgen synthesis; prenylation
资金
- Australian Research Council Future Fellowship [FT120100251]
- Avant Mutual Group Ltd.
- National Health and Medical Research Council [1008081]
- National Heart Foundation of Australia [G11S5757]
The role of statin therapy in prostate cancer (PCa) prevention and treatment is plagued by controversy. This critical review of published clinical series reveals several caveats in earlier studies, which reported no benefit. Recent studies that adjust for confounding factors have demonstrated statin therapy to be associated with PCa prevention and favorable clinical outcomes. Developed as inhibitors of cholesterol synthesis, the expected mechanism of statin action is systemic cholesterol reduction. By lowering circulating cholesterol, statins indirectly reduce cellular cholesterol levels in multiple cell types, impacting on membrane microdomains and steroidogenesis. Although non-cholesterol mechanisms of statin action have been proposed, they are limited by the uncertainties surrounding in vivo tissue statin concentrations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据